Cyclophosphamide and mycophenolate mofetil as induction therapy in lupus nephritis
Background/Aim: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multisystemic involvement. Almost 50 % of patients who suffer from systemic lupus erythematosus have lupus nephritis (LN) as well. Mycophenolate mofetil (MMF) or intravenous cyclophosphamide (CYC) are recommended...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical Society of the Republic of Srpska, Banja Luka, University of Banja Luka. Faculty of Medicine
2024-01-01
|
| Series: | Scripta Medica |
| Subjects: | |
| Online Access: | https://scindeks-clanci.ceon.rs/data/pdf/2490-3329/2024/2490-33292406743B.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832096587753455616 |
|---|---|
| author | Božić-Majstorović Ljubinka Popović-Pejičić Snježana Mrđa Jelena Mrđa Vladimir Ovčina Irma |
| author_facet | Božić-Majstorović Ljubinka Popović-Pejičić Snježana Mrđa Jelena Mrđa Vladimir Ovčina Irma |
| author_sort | Božić-Majstorović Ljubinka |
| collection | DOAJ |
| description | Background/Aim: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multisystemic involvement. Almost 50 % of patients who suffer from systemic lupus erythematosus have lupus nephritis (LN) as well. Mycophenolate mofetil (MMF) or intravenous cyclophosphamide (CYC) are recommended as preferred therapy. The aim of this study was to see how MMF and CYC, when compared, are efficient in dealing with LN. Methods: Study included 53 SLE patients with biopsy-proven class III and class IV LN. Twenty-two patients (42 %) were treated with MMF (dosage 2-3 g/day) and 31 patients (58 %) were treated with CYC (0.5 to 1.0 g/m2 in monthly pulses) in a 24-week induction study. Outcome of interest was the improvement in serum creatinine, proteinuria and creatinine clearance. Primary end point included complete renal remission defined as serum creatinine within 25 % of baseline before flare and proteinuria < 0.5 g/24 h. Secondary end point included complete renal remission in follow-up period. Results: The results revealed that response between two groups was not notably different (X2 = 0.151, p = 0.697). Four out of 22 patients (18.2 %) in MMF group and 7 out of 31 patients (22.6 %) in CYC group had complete renal remission. Most patients from both groups showed improvement from the clinical point of view. Secondary end point was also similar between treatment groups. Conclusion: The study showed same efficiency between these treatment groups, MMF and CYC as induction for LN. No crucial differences were identified between MMF and CYC groups in terms of renal remission. |
| format | Article |
| id | doaj-art-60bafb8c15cc4113903b9a666491c135 |
| institution | Kabale University |
| issn | 2490-3329 2303-7954 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Medical Society of the Republic of Srpska, Banja Luka, University of Banja Luka. Faculty of Medicine |
| record_format | Article |
| series | Scripta Medica |
| spelling | doaj-art-60bafb8c15cc4113903b9a666491c1352025-02-05T13:19:48ZengMedical Society of the Republic of Srpska, Banja Luka, University of Banja Luka. Faculty of MedicineScripta Medica2490-33292303-79542024-01-0155674374810.5937/scriptamed55-550412490-33292406743BCyclophosphamide and mycophenolate mofetil as induction therapy in lupus nephritisBožić-Majstorović Ljubinka0https://orcid.org/0009-0002-4654-0224Popović-Pejičić Snježana1https://orcid.org/0000-0002-6071-4860Mrđa Jelena2https://orcid.org/0009-0002-4307-036XMrđa Vladimir3https://orcid.org/0009-0000-8146-8614Ovčina Irma4https://orcid.org/0009-0007-0489-5576University of Banja Luka, Faculty of Medicine, Banja Luka, The Republic of Srpska, Bosnia and HerzegovinaUniversity of Banja Luka, Faculty of Medicine, Banja Luka, The Republic of Srpska, Bosnia and HerzegovinaUniversity of Banja Luka, Faculty of Medicine, Banja Luka, The Republic of Srpska, Bosnia and HerzegovinaUniversity of Banja Luka, Faculty of Medicine, Banja Luka, The Republic of Srpska, Bosnia and HerzegovinaUniversity of Banja Luka, Faculty of Medicine, Banja Luka, The Republic of Srpska, Bosnia and HerzegovinaBackground/Aim: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multisystemic involvement. Almost 50 % of patients who suffer from systemic lupus erythematosus have lupus nephritis (LN) as well. Mycophenolate mofetil (MMF) or intravenous cyclophosphamide (CYC) are recommended as preferred therapy. The aim of this study was to see how MMF and CYC, when compared, are efficient in dealing with LN. Methods: Study included 53 SLE patients with biopsy-proven class III and class IV LN. Twenty-two patients (42 %) were treated with MMF (dosage 2-3 g/day) and 31 patients (58 %) were treated with CYC (0.5 to 1.0 g/m2 in monthly pulses) in a 24-week induction study. Outcome of interest was the improvement in serum creatinine, proteinuria and creatinine clearance. Primary end point included complete renal remission defined as serum creatinine within 25 % of baseline before flare and proteinuria < 0.5 g/24 h. Secondary end point included complete renal remission in follow-up period. Results: The results revealed that response between two groups was not notably different (X2 = 0.151, p = 0.697). Four out of 22 patients (18.2 %) in MMF group and 7 out of 31 patients (22.6 %) in CYC group had complete renal remission. Most patients from both groups showed improvement from the clinical point of view. Secondary end point was also similar between treatment groups. Conclusion: The study showed same efficiency between these treatment groups, MMF and CYC as induction for LN. No crucial differences were identified between MMF and CYC groups in terms of renal remission.https://scindeks-clanci.ceon.rs/data/pdf/2490-3329/2024/2490-33292406743B.pdflupus erythematosus, systemiclupus nephritiscyclophosphamidemycophenolic acidmycophenolate mofetil |
| spellingShingle | Božić-Majstorović Ljubinka Popović-Pejičić Snježana Mrđa Jelena Mrđa Vladimir Ovčina Irma Cyclophosphamide and mycophenolate mofetil as induction therapy in lupus nephritis Scripta Medica lupus erythematosus, systemic lupus nephritis cyclophosphamide mycophenolic acid mycophenolate mofetil |
| title | Cyclophosphamide and mycophenolate mofetil as induction therapy in lupus nephritis |
| title_full | Cyclophosphamide and mycophenolate mofetil as induction therapy in lupus nephritis |
| title_fullStr | Cyclophosphamide and mycophenolate mofetil as induction therapy in lupus nephritis |
| title_full_unstemmed | Cyclophosphamide and mycophenolate mofetil as induction therapy in lupus nephritis |
| title_short | Cyclophosphamide and mycophenolate mofetil as induction therapy in lupus nephritis |
| title_sort | cyclophosphamide and mycophenolate mofetil as induction therapy in lupus nephritis |
| topic | lupus erythematosus, systemic lupus nephritis cyclophosphamide mycophenolic acid mycophenolate mofetil |
| url | https://scindeks-clanci.ceon.rs/data/pdf/2490-3329/2024/2490-33292406743B.pdf |
| work_keys_str_mv | AT bozicmajstorovicljubinka cyclophosphamideandmycophenolatemofetilasinductiontherapyinlupusnephritis AT popovicpejicicsnjezana cyclophosphamideandmycophenolatemofetilasinductiontherapyinlupusnephritis AT mrđajelena cyclophosphamideandmycophenolatemofetilasinductiontherapyinlupusnephritis AT mrđavladimir cyclophosphamideandmycophenolatemofetilasinductiontherapyinlupusnephritis AT ovcinairma cyclophosphamideandmycophenolatemofetilasinductiontherapyinlupusnephritis |